JPH08508719A - インシュリン依存型糖尿病の治療 - Google Patents
インシュリン依存型糖尿病の治療Info
- Publication number
- JPH08508719A JPH08508719A JP6518333A JP51833394A JPH08508719A JP H08508719 A JPH08508719 A JP H08508719A JP 6518333 A JP6518333 A JP 6518333A JP 51833394 A JP51833394 A JP 51833394A JP H08508719 A JPH08508719 A JP H08508719A
- Authority
- JP
- Japan
- Prior art keywords
- vla4
- antibody
- diabetes
- use according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.前糖尿病の個体におけるインシュリン依存型(I型)糖尿病の予防において 使用するための医薬の製造のための抗VLA4抗体の利用。 2.抗VLA4抗体をHP1/2、HP2/1、HP2/4、L25及びP4C 2からなる群より選択する、請求項1に記載の利用。 3.抗VLA4抗体がHP1/2、又はVLA4に結合し得るその断片である、 請求項1に記載の利用。 4.抗VLA4抗体がヒト化HP1/2抗体、又はVLA4に結合し得るその断 片である、請求項1に記載の利用。 5.医薬を、前糖尿病の個体の重量に基づいて約0.1〜10mg/kgで与え るような投与量で投与する、請求項1に記載の利用。 6.医薬を、1〜14日の期間にわたって末梢血液中のVLA4陽性細胞を被覆 するのに有効な量で投与する、請求項1に記載の利用。 7.医薬を、前糖尿病の個体における血漿中の抗体レベル少なくとも1μg/m lを与えるのに有効な量で投与する、請求項1に記載の利用。 8.医薬を、約250mg/dL未満の血清グルコースレベルの測定により明白 な糖尿病の発達の前に投与する、請求項1に記載の利用。 9.前糖尿病の個体がヒトである、請求項1に記載の利用。 10.糖尿病の治療において使用するための医薬の製造のための、抗体、組換え 抗体、キメラ抗体、VLA4のα4サブユニットに結合し得るかかる抗体の断片 、ポリペプチド若しくは低分子、又は前記のものの任意の組合せの利用。 11.抗体、ポリペプチド又は分子を、モノクローナル抗体HP1/2、かかる 抗体のFab、Fab'、F(ab')2若しくはF(v)断片、可溶性VCAM−1若しく はフィブロネクチンポリペプチド、又はVLA4のVCAM−1若しくはフィブ ロネクチン結合ドメインに結合する低分子から選択する、請求項10に記載の利 用。 12.医薬が複数の抗VLA4モノクローナル抗体又はそのVLA4結合性断片 を含む、請求項10に記載の利用。 13.医薬を、感受性の哺乳動物の重量に基づいて、約0.1〜10mg/kg の抗体、抗体断片、ポリペプチド又は低分子を与えるような投与量で投与する、 請求項10に記載の利用。 14.医薬を、1〜14日の期間にわたって、末梢血液中のVLA4陽性細胞を 被覆するのに有効な量で投与する、請求項10に記載の利用。 15.医薬を、1〜14日の期間にわたって、哺乳動物の血漿中の抗体レベル少 なくとも1μg/mlを与える のに有効な量で投与する、請求項10に記載の利用。 16.可溶性VCAM−1ポリペプチドがVCAM2D−IgGを含む、請求項 11に記載の利用。 17.本質的に、製薬上許容し得るキャリアー中のVLA4を認識するモノクロ ーナル抗体からなる、糖尿病の発症の予防を与えるのに有効な製薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2933093A | 1993-02-09 | 1993-02-09 | |
US08/029,330 | 1993-02-09 | ||
PCT/US1994/001456 WO1994017828A2 (en) | 1993-02-09 | 1994-02-09 | Treatment for insulin dependent diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08508719A true JPH08508719A (ja) | 1996-09-17 |
JP3593343B2 JP3593343B2 (ja) | 2004-11-24 |
Family
ID=21848497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51833394A Expired - Fee Related JP3593343B2 (ja) | 1993-02-09 | 1994-02-09 | インシュリン依存型糖尿病の治療 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5888507A (ja) |
EP (1) | EP0682529B2 (ja) |
JP (1) | JP3593343B2 (ja) |
AT (1) | ATE161730T1 (ja) |
AU (1) | AU687790B2 (ja) |
CA (1) | CA2155303C (ja) |
DE (1) | DE69407758T3 (ja) |
DK (1) | DK0682529T4 (ja) |
ES (1) | ES2114183T5 (ja) |
GR (1) | GR3026531T3 (ja) |
HK (1) | HK1008731A1 (ja) |
NZ (1) | NZ262615A (ja) |
WO (1) | WO1994017828A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515594A (ja) * | 2003-01-07 | 2006-06-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ランゲルハンス島細胞数を増加させることによって糖尿病を治療するためのキヌレニン3−ヒドロキシラーゼ阻害剤 |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2148712C (en) | 1992-11-13 | 2012-01-17 | Thalia Papayannopoulou | Peripheralization of hematopoietic stem cells |
DE69419721T2 (de) * | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
US5677291A (en) * | 1993-12-10 | 1997-10-14 | Hoechst Marion Roussel, Inc. | Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols |
US5750336A (en) * | 1994-02-10 | 1998-05-12 | The Salk Institute For Biological Studies | Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US5608095A (en) * | 1996-04-30 | 1997-03-04 | Hoechst Marion Roussel, Inc. | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
US5795876A (en) * | 1996-04-30 | 1998-08-18 | Hoechst Marion Rousssel, Inc. | Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US6114572A (en) * | 1996-11-20 | 2000-09-05 | Hoechst Marion Roussel, Inc. | Substituted phenols and thiophenols useful as antioxidant agents |
ES2289778T3 (es) * | 1997-04-18 | 2008-02-01 | Biogen Idec Ma Inc. | Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii. |
US6121463A (en) * | 1997-06-24 | 2000-09-19 | Hoechst Marion Roussel, Inc. | Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents |
US6133467A (en) * | 1997-06-25 | 2000-10-17 | Hoechst Marion Roussel, Inc. | 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
PL203114B1 (pl) | 1998-09-14 | 2009-08-31 | Regents Board Of | Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1 |
US6110109A (en) * | 1999-03-26 | 2000-08-29 | Biosignia, Inc. | System and method for predicting disease onset |
IL145898A0 (en) | 1999-04-22 | 2002-07-25 | Biogen Inc | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
EA011384B1 (ru) | 1999-06-01 | 2009-02-27 | Байоджен Айдек Ма Инк. | Способ лечения воспалительного заболевания |
DK1214091T3 (da) * | 1999-09-14 | 2006-08-28 | Biogen Idec Inc | Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister |
US20010046489A1 (en) | 1999-12-06 | 2001-11-29 | Habener Joel E. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US20060115473A1 (en) * | 2000-12-14 | 2006-06-01 | Biogen Idec Ma Inc., A Massachusetts Corporation | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
ES2415708T3 (es) | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
JP3459609B2 (ja) * | 2000-03-17 | 2003-10-20 | 三洋電機株式会社 | ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法 |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
US7576101B2 (en) | 2003-01-24 | 2009-08-18 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
CN103169965A (zh) | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
NZ556105A (en) * | 2004-12-03 | 2009-12-24 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
AU2006316629A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with alpha 4 beta 7 integrin |
DK2034830T3 (da) | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | Anti-vla-1-antistof til behandling af slagtilfælde |
MX2009013593A (es) | 2007-06-14 | 2010-01-20 | Biogen Idec Inc | Formulaciones de anticuerpos. |
EP2200611A4 (en) | 2007-09-14 | 2010-09-22 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY (PML) |
EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
MX2011010971A (es) * | 2009-04-17 | 2012-01-19 | Biogen Idec Inc | Composiciones y metodos para tratar leucemia mielogena aguda. |
EP2467159A1 (en) | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
EP2485762B1 (en) | 2009-10-11 | 2017-12-13 | Biogen MA Inc. | Anti-vla-4 related assays |
AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
UY34054A (es) | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
EP3575311A1 (en) | 2012-03-20 | 2019-12-04 | Biogen MA Inc. | Jcv neutralizing antibodies |
EP2845134A1 (en) | 2012-04-20 | 2015-03-11 | Biogen Idec MA Inc. | Cognitive composite parameters and uses thereof for evaluating multiple sclerosis |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
EP2883177A1 (en) | 2012-08-13 | 2015-06-17 | Biogen Idec MA Inc. | Disease progression parameters and uses thereof for evaluating multiple sclerosis |
EP3750560A3 (en) | 2012-10-09 | 2021-03-24 | Biogen MA Inc. | Combination therapies and uses for treatment of demyelinating disorders |
WO2015063604A2 (en) | 2013-11-01 | 2015-05-07 | Imberti Luisa | BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
AU2017297404A1 (en) | 2016-07-13 | 2019-01-24 | Biogen Ma Inc. | Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders |
WO2018045162A1 (en) | 2016-09-01 | 2018-03-08 | Biogen Ma Inc. | Biomarkers predictive of primary progressive multiple sclerosis and uses thereof |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
CA3133072A1 (en) | 2019-03-11 | 2020-09-17 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-lingo-1 antibodies |
WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US4879313A (en) * | 1988-07-20 | 1989-11-07 | Mosanto Company | Novel platelet-aggregation inhibitors |
US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
JPH04501565A (ja) * | 1988-11-14 | 1992-03-19 | ブリガム・アンド・ウイメンズ・ホスピタル | Elam―1に特異的な抗体およびその用途 |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5217870A (en) * | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5061693A (en) * | 1989-07-28 | 1991-10-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
IL113261A (en) † | 1989-09-01 | 1996-10-16 | Hutchinson Fred Cancer Res | Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing |
US4952562A (en) * | 1989-09-29 | 1990-08-28 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptides and pseudopeptides |
US5053392A (en) * | 1989-12-01 | 1991-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors |
US5260277A (en) * | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1993008823A1 (en) * | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
ATE150319T1 (de) * | 1992-01-13 | 1997-04-15 | Biogen Inc | Behandlung von asthma |
WO1993015764A1 (en) * | 1992-02-12 | 1993-08-19 | Biogen, Inc. | Treatment for inflammatory bowel disease |
CA2148712C (en) * | 1992-11-13 | 2012-01-17 | Thalia Papayannopoulou | Peripheralization of hematopoietic stem cells |
US5591719A (en) * | 1992-12-10 | 1997-01-07 | Regents Of The University Of Minnesota | Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity |
DE69419721T2 (de) * | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
KR100367948B1 (ko) * | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
-
1994
- 1994-02-09 AU AU62379/94A patent/AU687790B2/en not_active Ceased
- 1994-02-09 DE DE69407758T patent/DE69407758T3/de not_active Expired - Lifetime
- 1994-02-09 AT AT94909584T patent/ATE161730T1/de active
- 1994-02-09 ES ES94909584T patent/ES2114183T5/es not_active Expired - Lifetime
- 1994-02-09 NZ NZ262615A patent/NZ262615A/en not_active IP Right Cessation
- 1994-02-09 EP EP94909584A patent/EP0682529B2/en not_active Expired - Lifetime
- 1994-02-09 CA CA2155303A patent/CA2155303C/en not_active Expired - Fee Related
- 1994-02-09 DK DK94909584T patent/DK0682529T4/da active
- 1994-02-09 WO PCT/US1994/001456 patent/WO1994017828A2/en active IP Right Grant
- 1994-02-09 JP JP51833394A patent/JP3593343B2/ja not_active Expired - Fee Related
-
1995
- 1995-05-22 US US08/447,118 patent/US5888507A/en not_active Expired - Lifetime
-
1998
- 1998-04-03 GR GR980400715T patent/GR3026531T3/el unknown
- 1998-07-06 HK HK98108899A patent/HK1008731A1/xx not_active IP Right Cessation
-
2005
- 2005-04-11 US US11/103,362 patent/US20050208053A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515594A (ja) * | 2003-01-07 | 2006-06-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ランゲルハンス島細胞数を増加させることによって糖尿病を治療するためのキヌレニン3−ヒドロキシラーゼ阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
JP3593343B2 (ja) | 2004-11-24 |
CA2155303A1 (en) | 1994-08-18 |
AU687790B2 (en) | 1998-03-05 |
ATE161730T1 (de) | 1998-01-15 |
DE69407758T2 (de) | 1998-08-27 |
CA2155303C (en) | 2010-04-20 |
EP0682529A1 (en) | 1995-11-22 |
WO1994017828A2 (en) | 1994-08-18 |
NZ262615A (en) | 1996-02-27 |
AU6237994A (en) | 1994-08-29 |
EP0682529B2 (en) | 2005-12-28 |
HK1008731A1 (en) | 1999-05-14 |
ES2114183T3 (es) | 1998-05-16 |
EP0682529B1 (en) | 1998-01-07 |
DK0682529T4 (da) | 2006-05-15 |
GR3026531T3 (en) | 1998-07-31 |
DE69407758D1 (de) | 1998-02-12 |
US5888507A (en) | 1999-03-30 |
WO1994017828A3 (en) | 1994-10-13 |
US20050208053A1 (en) | 2005-09-22 |
ES2114183T5 (es) | 2006-06-16 |
DE69407758T3 (de) | 2007-05-24 |
DK0682529T3 (da) | 1998-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08508719A (ja) | インシュリン依存型糖尿病の治療 | |
Krueger | The immunologic basis for the treatment of psoriasis with new biologic agents | |
Comer et al. | Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival | |
US5885579A (en) | CTLA4 receptor and uses thereof | |
JP4391558B2 (ja) | T細胞における抗原特異性アポトーシスの誘導のためのリガンド | |
KR100912994B1 (ko) | Nkg2d의 조절 | |
JPH0769914A (ja) | 免疫応答調節組成物 | |
JP2003520828A (ja) | Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用 | |
US20080095774A1 (en) | Agents and Methods for Specifically Blocking CD28-Mediated Signaling | |
US20120269806A1 (en) | Methods of inducing tolerance | |
JP2002540764A (ja) | B7分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法 | |
US7070776B1 (en) | Methods for blocking binding of CD28 receptor to B7 | |
WO1996014865A1 (en) | Methods for inhibiting graft versus host disease in bone marrow transplantation | |
US9115198B2 (en) | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof | |
MXPA01012388A (es) | Anticuerpo monoclonal bloqueador para vla-1 y su uso para el tratamiento de trastornos inflamatorios. | |
JP2003128579A (ja) | 特定種のlfa−3またはcd2結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法 | |
KR20140043795A (ko) | 가용성 인테그린 α4 변이체 | |
AU727187B2 (en) | Treatment for insulin dependent diabetes | |
US20230128075A1 (en) | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof | |
JP4808841B2 (ja) | T細胞活性化および増殖を阻害するLO−CD2a抗体およびその使用法 | |
CN117986365A (zh) | 一种抗犬pd-1单克隆抗体及其应用 | |
CN118234501A (zh) | 用于靶向调节性t细胞以治疗自身免疫病的滑膜细胞外基质特异性嵌合抗原受体 | |
AU784510B2 (en) | Methods for modulating T cell unresponsiveness | |
WO2001030377A1 (en) | Porcine b7-1 and antibodies thereto | |
Doll | Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040602 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040803 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040830 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080903 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090903 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100903 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110903 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110903 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120903 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |